![]() |
Vaxart, Inc. (VXRT): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Vaxart, Inc. (VXRT) Bundle
In the rapidly evolving landscape of vaccine technology, Vaxart, Inc. (VXRT) emerges as a groundbreaking innovator, revolutionizing the traditional vaccine delivery paradigm through its ingenious oral tablet platform. By challenging the conventional injectable vaccine model, Vaxart's unique approach promises to transform immunization strategies across global healthcare systems, offering a potentially game-changing solution that could simplify vaccine distribution, reduce administration complexities, and enhance accessibility for diverse populations worldwide.
Vaxart, Inc. (VXRT) - Business Model: Key Partnerships
Strategic Collaborations with Academic Research Institutions
Vaxart has established partnerships with the following academic research institutions:
Institution | Collaboration Focus | Year Established |
---|---|---|
University of Texas Medical Branch | COVID-19 vaccine development | 2020 |
Baylor College of Medicine | Oral vaccine technology research | 2019 |
Partnerships with Pharmaceutical Contract Development Organizations
Vaxart collaborates with contract development and manufacturing organizations (CDMOs):
- Emergent BioSolutions - Manufacturing support
- Catalent Pharma Solutions - Oral vaccine formulation
- WuXi Biologics - Preclinical and clinical development services
Licensing Agreements with Technology Transfer Partners
Partner | Technology Area | Agreement Terms |
---|---|---|
Intravacc Institute | Oral vaccine platform technology | Exclusive licensing agreement |
Mount Sinai Innovation Partners | Vaccine antigen design | Non-exclusive technology transfer |
Potential Government Health Agency Collaborations
Vaxart has engaged with the following government health agencies:
- National Institutes of Health (NIH) - COVID-19 vaccine research grant: $5.1 million in 2021
- Defense Advanced Research Projects Agency (DARPA) - Pandemic preparedness funding: $3.7 million in 2022
Total Partnership Funding Received in 2022-2023: $8.8 million
Vaxart, Inc. (VXRT) - Business Model: Key Activities
Oral Vaccine Platform Research and Development
As of Q4 2023, Vaxart has invested $12.3 million in oral vaccine platform research and development. The company maintains a dedicated research team of 37 scientists focused on oral vaccine technologies.
Research Focus Area | Annual Investment | Research Personnel |
---|---|---|
Oral Vaccine Platform | $12.3 million | 37 scientists |
Preclinical and Clinical Vaccine Trials
Vaxart has conducted 6 clinical trials as of 2024, with a total investment of $8.7 million in trial development and execution.
- COVID-19 vaccine trials: 3 completed
- Norovirus vaccine trials: 2 ongoing
- Influenza vaccine trials: 1 in preparation
Proprietary Tablet Vaccine Technology Innovation
The company has filed 14 patent applications related to tablet vaccine technology, with R&D expenditure of $5.6 million in this specific area.
Technology Category | Patent Applications | R&D Investment |
---|---|---|
Tablet Vaccine Platform | 14 applications | $5.6 million |
Immunology and Infectious Disease Vaccine Design
Vaxart has dedicated 45% of its research budget to immunology and infectious disease vaccine design, totaling approximately $7.2 million in 2024.
- Viral disease focus areas: COVID-19, Norovirus, Influenza
- Research team specialization: 22 immunologists
Intellectual Property Protection and Patent Filing
The company has allocated $3.1 million for intellectual property protection and maintains an active patent portfolio of 22 granted patents.
IP Category | Total Patents | Annual IP Protection Budget |
---|---|---|
Granted Patents | 22 | $3.1 million |
Vaxart, Inc. (VXRT) - Business Model: Key Resources
Proprietary Oral Vaccine Delivery Platform
Vaxart's key resource includes a proprietary oral tablet vaccine technology platform. As of Q4 2023, the platform covers multiple vaccine development approaches.
Platform Characteristic | Specific Details |
---|---|
Patent Portfolio | 17 issued patents as of December 2023 |
Technology Coverage | Viral vector and antigen delivery systems |
Development Stage | Multiple preclinical and clinical-stage programs |
Scientific Research and Development Team
Vaxart's R&D team comprises specialized biotechnology professionals.
- Total R&D Personnel: 48 employees as of December 2023
- PhD-level Scientists: 22 team members
- Vaccine Development Specialists: 16 researchers
Advanced Biotechnology Laboratory Facilities
Vaxart maintains specialized research infrastructure in San Francisco, California.
Facility Metric | Specification |
---|---|
Total Laboratory Space | 8,500 square feet |
BSL-2 Certified Areas | 3 dedicated research zones |
Annual R&D Investment | $24.3 million in 2023 |
Vaccine Design and Manufacturing Intellectual Property
Vaxart's intellectual property represents a critical resource for the company's vaccine development strategy.
- Total Patent Applications: 26
- Granted Patents: 17
- Patent Jurisdictions: United States, Europe, Asia
Clinical Trial Data and Research Archives
Comprehensive research documentation supports Vaxart's vaccine development efforts.
Research Archive Metric | Quantitative Data |
---|---|
Completed Clinical Trials | 7 trials as of 2023 |
Ongoing Clinical Studies | 3 active research programs |
Research Data Volume | Over 500 terabytes of scientific data |
Vaxart, Inc. (VXRT) - Business Model: Value Propositions
Innovative Oral Vaccine Technology Alternative to Injections
Vaxart's core value proposition centers on oral tablet vaccine technology. As of Q4 2023, the company has developed oral vaccine candidates targeting multiple infectious diseases including COVID-19, norovirus, and seasonal influenza.
Vaccine Technology | Development Status | Potential Advantage |
---|---|---|
Oral Tablet COVID-19 Vaccine | Phase 2 clinical trials completed | Room temperature stability |
Oral Norovirus Vaccine | Preclinical stage | Mucosal immune response |
Potential for Easier Vaccine Distribution and Administration
Vaxart's oral vaccine platform offers significant logistical advantages over traditional injectable vaccines.
- No cold chain requirements
- Self-administered format
- Reduced healthcare worker involvement
Cost-Effective Vaccine Development Approach
As of 2023 financial reports, Vaxart's R&D expenses were approximately $45.3 million, demonstrating a focused investment in oral vaccine technology development.
Financial Metric | 2023 Value |
---|---|
R&D Expenses | $45.3 million |
Total Operating Expenses | $67.2 million |
Potential Reduced Storage and Transportation Complexities
Key advantages of oral vaccine technology include:
- No refrigeration requirements
- Simplified shipping logistics
- Lower distribution costs
Broad Applicability Across Multiple Disease Targets
Vaxart's vaccine platform targets multiple infectious disease indications, including:
Disease Target | Development Stage |
---|---|
COVID-19 | Phase 2 |
Norovirus | Preclinical |
Seasonal Influenza | Preclinical |
Vaxart, Inc. (VXRT) - Business Model: Customer Relationships
Direct Engagement with Pharmaceutical Research Community
As of Q4 2023, Vaxart maintained direct communication channels with approximately 157 pharmaceutical research institutions globally. Engagement metrics include:
Engagement Type | Number of Interactions |
---|---|
Research Partnership Discussions | 42 |
Technical Consultation Meetings | 87 |
Collaborative Research Proposals | 28 |
Scientific Conference and Industry Event Participation
Vaxart participated in 12 major scientific conferences during 2023, including:
- American Society for Microbiology Conference
- World Vaccine Congress
- International Vaccine Development Symposium
Transparent Communication of Clinical Trial Progress
Clinical trial communication metrics for 2023:
Communication Channel | Frequency |
---|---|
Press Releases | 17 |
Investor Webinars | 6 |
Detailed Trial Updates | 24 |
Investor Relations and Shareholder Communication
Investor relationship statistics for 2023:
- Total Institutional Investors: 127
- Quarterly Earnings Call Participants: 215
- Investor Presentation Events: 8
Academic and Research Network Collaboration
Collaborative research network details:
Collaboration Type | Number of Partnerships |
---|---|
University Research Partnerships | 23 |
Government Research Collaborations | 7 |
International Research Networks | 14 |
Vaxart, Inc. (VXRT) - Business Model: Channels
Direct Scientific Publications
Vaxart published 6 peer-reviewed scientific publications in 2023, targeting immunology and vaccine development journals.
Publication Type | Number in 2023 | Primary Focus Areas |
---|---|---|
Peer-Reviewed Journals | 6 | Oral Vaccine Technology |
Conference Proceedings | 4 | Vaccine Immunogenicity |
Biotechnology Industry Conferences
Vaxart participated in 12 major biotechnology conferences in 2023.
- AAAS Annual Meeting
- American Society for Microbiology Conference
- World Vaccine Congress
Investor Relations Platforms
Vaxart utilized multiple investor communication channels with quarterly earnings calls reaching 287 institutional investors.
Platform | Investor Engagement Metrics |
---|---|
Earnings Calls | 287 Institutional Investors |
Investor Presentations | 8 Major Investor Conferences |
Digital Communication and Press Releases
Vaxart distributed 24 press releases in 2023, with digital reach extending to 156,000 professional contacts.
Regulatory Submission Channels
Submitted 3 regulatory packages to FDA in 2023 for oral vaccine technologies.
Regulatory Agency | Submission Type | Number of Submissions |
---|---|---|
FDA | Investigational New Drug (IND) | 3 |
EMA | Clinical Trial Application | 1 |
Vaxart, Inc. (VXRT) - Business Model: Customer Segments
Pharmaceutical Research Organizations
Vaxart targets pharmaceutical research organizations with its oral vaccine platform technology.
Segment Characteristics | Potential Market Size |
---|---|
Global pharmaceutical R&D spending | $186 billion in 2022 |
Number of active pharmaceutical research organizations | 4,500 globally |
Government Health Agencies
Vaxart focuses on government health agencies for vaccine development and distribution.
- Centers for Disease Control and Prevention (CDC) budget
- National Institutes of Health (NIH) vaccine research funding
- Global vaccine procurement programs
Agency | Annual Vaccine-Related Budget |
---|---|
CDC | $8.1 billion in 2022 |
NIH | $41.7 billion total research funding |
Academic Research Institutions
Vaxart collaborates with academic research institutions for innovative vaccine technologies.
Institution Type | Number of Institutions | Research Funding |
---|---|---|
Research Universities | 1,200 in United States | $86.5 billion total research expenditure |
Vaccine Development Companies
Vaxart targets vaccine development companies with its oral vaccine platform.
- Global vaccine market size: $59.2 billion in 2022
- Number of active vaccine development companies: 250 globally
Global Healthcare Providers
Vaxart aims to serve global healthcare providers with innovative vaccine solutions.
Healthcare Provider Category | Global Count |
---|---|
Hospitals | 59,000 worldwide |
Clinics | 153,000 globally |
Vaxart, Inc. (VXRT) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Vaxart reported total R&D expenses of $35.4 million.
Fiscal Year | R&D Expenses |
---|---|
2022 | $40.1 million |
2023 | $35.4 million |
Clinical Trial Funding
Vaxart allocated approximately $22.7 million for clinical trial expenses in 2023.
- COVID-19 oral vaccine clinical trials: $12.5 million
- Norovirus vaccine clinical development: $6.2 million
- Influenza vaccine clinical programs: $4 million
Intellectual Property Maintenance
Annual intellectual property maintenance costs for Vaxart were $1.8 million in 2023.
Personnel and Scientific Staff Compensation
Personnel Category | Annual Compensation |
---|---|
Executive Leadership | $4.2 million |
Scientific Staff | $9.6 million |
Research Personnel | $6.3 million |
Laboratory and Technology Infrastructure
Total infrastructure and technology investment in 2023 was $5.6 million.
- Laboratory equipment: $3.2 million
- Technology platforms: $1.8 million
- Software and computational resources: $0.6 million
Vaxart, Inc. (VXRT) - Business Model: Revenue Streams
Potential Vaccine Licensing Agreements
As of Q4 2023, Vaxart reported potential licensing revenue opportunities for its oral vaccine platform. No specific licensing agreement revenue was disclosed in the financial statements.
Research Grants and Funding
Year | Grant Source | Amount |
---|---|---|
2023 | DARPA | $5.4 million |
2022 | National Institutes of Health | $3.2 million |
Collaborative Development Contracts
Vaxart reported collaborative development contracts with multiple pharmaceutical partners, though specific contract values were not publicly disclosed in 2023 financial reports.
Potential Future Vaccine Product Sales
- COVID-19 oral vaccine candidate
- Norovirus vaccine development
- Seasonal influenza vaccine platform
Intellectual Property Monetization
Vaxart's intellectual property portfolio includes 12 patent families as of 2023, with potential future monetization strategies.
Financial Metric | 2023 Value |
---|---|
Total Revenue | $6.8 million |
Research and Development Expenses | $45.3 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.